Jeng Her, PhD

CEO

• Dr. Jeng Her is the founder and CEO of AP Biosciences. He had received a bachelor’s degree in Physics from the National Taiwan University, then turned into biology and earned a Ph.D. degree in Microbiology and Immunology from the University of Virginia in 1993.
• Before setting up AP Biosciences in Taiwan, he had co-founded KaloBios Pharmaceuticals in the Silicon Valley soon after his post-doctoral training at Bristol-Myers Squibb and DNAX Research Institute (now part of Merck). At KaloBios, he co-invented the antibody Humaneering™, a technology which converts non-human antibodies into engineered human-like antibodies with sequences close to the germline to minimize immunogenicity. The technology was then licensed to Novartis non-exclusively for $32M. In 2013, KaloBios went public on NASDAQ with three antibodies in clinical trials, including KB001 for ventilator-associated pneumonia, which was licensed to Sanofi-Pasteur for $270 million.

Jon-Jih Liao, MD

VP of Biologics Development

• Dr. Jon-Jih Liao received his M.D. degree from the National Taiwan University in 1990 and completed a residency in family medicine at the National Taiwan University Hospital in 1995. In 1999, he founded the Department of Family Medicine at the New Taipei City Hospital.
• In July 2005, Dr. Liao changed his career path and became a Medical Reviewer in the Office of Clinical Science, Center for Drug Evaluation, Taiwan, and subsequently the Team Leader of the IND Review Team in December 2006.
• After decades of clinical practice and public services, he had decided to join private sector and became a Medical Advisor for Bristol-Myers Squibb and Eli Lilly in the fields of oncology and diabetology, then a Medical Director at OBI Pharma responsible for early stage clinical development of OBI-888 before joining AP Biosciences.

Jhong-Jhe You, PhD

VP of Antibody Discovery

• Dr. You received his Ph.D. degree on Molecule Medicine from the National Taiwan University, then extended his research in antibody engineering for functionality and stability at the Genomic Research Center, Academia Sinica before joining AP Biosciences.
• In 2013, he joined APBio as the first employee of the company, leading the effort on generation of the human antibody phage display library, Omni-Mab, as well as development of cell-based assay platform for screening & isolation of functional antibodies for immunotherapy. One major task under his scientific and technical leadership is to take antibody discovery through IND-enabling studies for selection of lead candidates into clinical development. In the meantime, he was also responsible for the application and execution of two SBIR (Small Business Innovation Research) grants for development of anti-inflammation biologics.

Tony Lin

Director of Accounting & Finance

• Master of Accounting, Georgia State University.
• Former Manager of Provision Co.

Winnie Tseng

Director of Administration

• MBA of Takming University of Science and Technology.
• Former Manager of Fiberpure Co.

Kenneth Liu

Supervisor of Dept. Procurement

• Master of Department of Harbor and River Engineering, Taiwan Ocean University.
• Former manager of stem cell pharmaceutical company.

Anna Chiang

Supervisor of Dept. Legal

• Master of Department of Law, National ChengChi University.
• Former manager of LexNovia International IP Law Firm.

Jeff Cheng

Supervisor of Dept. IT

• Bachelor of Science，CHING KUO INSTITUTE OF MANAGEMENT AND HEALTH.